BioNTech SE (ETR:22UA)
Germany
· Delayed Price · Currency is EUR | Market Cap | 21.90B |
| Revenue (ttm) | 2.75B |
| Net Income (ttm) | -766.00M |
| Shares Out | n/a |
| EPS (ttm) | -3.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 602 |
| Average Volume | 2,749 |
| Open | 90.65 |
| Previous Close | 92.15 |
| Day's Range | 90.60 - 91.90 |
| 52-Week Range | 69.70 - 124.60 |
| Beta | 1.29 |
| RSI | 50.63 |
| Earnings Date | Aug 4, 2025 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
Key deals this week: BioNTech, UnitedHealth, Qualcomm, Papa John's and more
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer
The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA candidates. Click for my look at BNTX and CVAC.
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE (NASDAQ: BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ: CVAC) in an all-stock transaction . According to the agreement, shareholders can exchange CureVac shares for around $5....
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Thursday. Shares of CureVac N.V. (NASDAQ: CVAC) rose sharply during Thursday's session after BioNTech announced it will acquir...
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments
CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the terms of the proposed transact...
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.
BioNTech to buy German rival CureVac for $1.25B in all-stock deal
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitiv...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
BioNTech's Deal With Bristol Myers Over BNT-327 May Be Overhyped
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Bristol Myers CEO explains why he's spending billions on BioNTech deal
Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ann...
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Why BioNTech Stock Soared Today
Bristol Myers Squibb just agreed to shower BioNTech with cash.
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The comp...
BioNTech to license bispecific antibody to Bristol in up to $11.1B deal
Stocks making the biggest moves midday: Tesla, BioNTech, DraftKings, Steel Dynamics and more
These are some of the stocks posting the largest moves in midday trading.